Compare American Airlines Group Inc (AAL) vs ADMA Biologics Inc (ADMA) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
American Airlines Group Inc vs ADMA Biologics Inc — how do they compare? American Airlines Group Inc trades at $16.58 (market cap $11.38B), while ADMA Biologics Inc trades at $9.28 (market cap $2.13B). The key difference: American Airlines Group Inc is far larger — about 5.3× ADMA Biologics Inc's market cap, and American Airlines Group Inc is trading nearer its 52-week high, ADMA Biologics Inc nearer its low. Which is the better fit depends on your goals.
| AAL | ADMA | |
|---|---|---|
Market Cap | $11.38B | $2.13B |
Sector | Industrials | Health |
52-Week High | $18.15 | $20.38 |
52-Week Low | $10.18 | $7.60 |
Enterprise Value | $38.97B | $2.20B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
American Airlines (AAL) trades at $17.20, down 4.02% amid sector rotation. The stock shows a bullish technical signal with strong moving average alignment, though RSI levels are mixed. Fundamentally, revenue grew to $54.63B in 2025, but net income fell sharply to $111M, reflecting margin pressure. Recent news highlights airline sector volatility, with fuel cost declines offering relief but broader market sentiment weighing on travel stocks.
Outlook remains cautious; analyst consensus is split with a $19.96 price target suggesting modest upside. Key risks include volatile fuel prices, competitive pressures, and high debt levels. Earnings consistency is critical for sustained recovery, with Q2 2026 results pivotal for confirming operational improvements.
ADMA trades at $9.16, up 2.35% today, with a bullish technical signal from moving averages and oscillators. The company reported strong profitability with a 32.43% net income margin and 43.3% ROE for 2025, though recent EPS results were mixed. Analyst consensus is strongly bullish with an $19.00 price target, but multiple class action lawsuits filed in July 2026 alleging securities fraud create significant near-term uncertainty.
The stock offers substantial upside to analyst targets if legal challenges are resolved favorably, supported by robust fundamentals and projected cash flow growth. Primary risks include the outcome of ongoing litigation and potential reputational damage. Investors should weigh strong financial performance against elevated legal and sentiment risks before establishing a position.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About American Airlines Group Inc
American Airlines is the world's largest airline by scheduled revenue passenger miles. The firm's major hubs are Charlotte, Chicago, Dallas/Fort Worth, Los Angeles, Miami, New York, Philadelphia, Phoenix, and Washington, D.C. After completing a major fleet renewal, the company has the youngest fleet of U.S. legacy carriers.
Read more on AAL →About ADMA Biologics Inc
ADMA Biologics is a biopharmaceutical company specializing in plasma-derived therapies for immunodeficient patients. Key products like ASCENIV and BIVIGAM treat primary humoral immunodeficiency and help prevent infectious diseases.
Read more on ADMA →
